id stringlengths 14 15 | text stringlengths 51 2.13k | source stringlengths 44 128 |
|---|---|---|
53fd6db4ff6b-2 | Precautions
The oral live-attenuated polio vaccine is no longer available in Australia due to the potential low risk (1 case per 2.4 million doses) of Vaccine Associated Paralytic Poliomyelitis (VAPP), also known as Vaccine Derived Poliovirus (VDPV). Following receipt of the oral polio vaccine some of the vaccine virus... | mvec.mcri.edu.au/references/polio/index.html |
f30468629881-0 | MVEC supports all scientific efforts to rapidly develop safe and effective SARS CoV-2 vaccine(s). This includes technology developed over 50 years ago and has been a proven way to support the production of viral vaccines that have saved so many lives around the world.
Background
In the early 1960’s foetal embryo fibrob... | mvec.mcri.edu.au/references/foetal-embryonic-cells-utilised-in-vaccine-development-platforms/index.html |
f30468629881-1 | Why don’t we try to use vaccines without these foetal embryonic cell lines?
The SARS CoV-2 pipeline is progressing at pandemic speed and it was important to utilise proven technologies to support vaccine development. Replication of viruses in the laboratory can be difficult, so these established platforms, as detailed ... | mvec.mcri.edu.au/references/foetal-embryonic-cells-utilised-in-vaccine-development-platforms/index.html |
f30468629881-2 | Resources
Children’s Hospital of Philadelphia, Vaccine Education Centre: Vaccine Ingredients- fetal tissues
Children’s Hospital of Philadelphia, Vaccine Education Centre: News & Views- Why were fetal cells used to make certain vaccines?
Johns Hopkins Bloomberg School of Public Health, Institute for Vaccine Safety: Reli... | mvec.mcri.edu.au/references/foetal-embryonic-cells-utilised-in-vaccine-development-platforms/index.html |
646d818143f9-0 | What is it?
COVID-19 disease is caused by the highly contagious SARS-CoV-2 virus, a type of coronavirus discovered in 2019 that spread rapidly resulting in a global pandemic. Multiple strains of SARS-CoV-2 have since emerged and public health authorities continue to monitor these. The Omicron strain is currently the mo... | mvec.mcri.edu.au/references/covid-19-vaccine-candidate-novavax/index.html |
646d818143f9-1 | Some individuals can experience ongoing symptoms for weeks or months after their initial diagnosis, this is known as long COVID or post-COVID conditions. Symptoms can include extreme fatigue, post-exertional malaise, dyspnoea, chest pain, palpitations, fever, arthralgia (joint pain), paresthesia (pins and needles), ras... | mvec.mcri.edu.au/references/covid-19-vaccine-candidate-novavax/index.html |
646d818143f9-2 | How is it transmitted?
Transmission of COVID-19 is through the inhalation of virus particles which have been made airborne after an infected person coughs, sneezes, breathes, speaks or sings. Droplets or particles can contaminate surfaces and can be spread when a person touches these surfaces and then touches their nos... | mvec.mcri.edu.au/references/covid-19-vaccine-candidate-novavax/index.html |
646d818143f9-3 | Primary course
A primary course of vaccination is recommended for all individuals from 5 years of age. Immune competent (those with a functioning immune system) individuals should receive 2 doses given 8 weeks apart, whereas those with immunocompromise should receive 3 doses, with 8 weeks between each dose.
Children ag... | mvec.mcri.edu.au/references/covid-19-vaccine-candidate-novavax/index.html |
646d818143f9-4 | Vaccines brands available for use by age group
Age group Vaccine brand Comirnaty (Pfizer- original) [maroon cap] Comirnaty (Pfizer- original) [orange cap] Comirnaty (Pfizer- original) [purple cap] Comirnaty (Pfizer bivalent- original/BA.1) [grey cap] Comirnaty (Pfizer bivalent- original/BA.4/5) [grey cap] Spikevax (Mod... | mvec.mcri.edu.au/references/covid-19-vaccine-candidate-novavax/index.html |
646d818143f9-5 | Rare side effects
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) are rare conditions that have been reported following administration of COVID-19 vaccines. They are most commonly associated with viral infections (including COVID-19 disease) but can also b... | mvec.mcri.edu.au/references/covid-19-vaccine-candidate-novavax/index.html |
646d818143f9-6 | Where can I access COVID-19 vaccines?COVID-19 vaccines can be accessed through GP clinics, some pharmacies (for vaccine recipients aged ≥ 5 years) and hospital immunisation services at Monash Children’s Hospital, the Royal Children’s Hospital and Joan Kirner Women’s and Children’s Hospital (Sunshine). To find your clos... | mvec.mcri.edu.au/references/covid-19-vaccine-candidate-novavax/index.html |
646d818143f9-7 | How do we complete a primary course of vaccination for children aged 6 months - ≤ 4 years who commenced their course with Spikevax (Moderna) `{`original/ancestral`}` now that it is no longer available?Immune competent children who commenced their primary course with 1 dose of Spikevax (Moderna), can complete their prim... | mvec.mcri.edu.au/references/covid-19-vaccine-candidate-novavax/index.html |
646d818143f9-8 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/covid-19-vaccine-candidate-novavax/index.html |
391a7ea2a3a4-0 | What is it?
Tuberculosis (TB) is caused by an infection with the bacteria Mycobacterium tuberculosis. In rarer cases, TB may be attributed to infection with Mycobacterium bovis or Mycobacterium africanum.
TB is categorised as being an active disease (the infected person is displaying symptoms and is infectious) or a la... | mvec.mcri.edu.au/references/bcg-vaccine/index.html |
391a7ea2a3a4-1 | A person is considered infectious until 14 days after being on active treatment AND until they have tested negative on a sputum sample. Following an active infection the bacteria will remain dormant (non-infectious) within scar tissue where it can be reactivated later in life (even decades later). Once reactivated the ... | mvec.mcri.edu.au/references/bcg-vaccine/index.html |
391a7ea2a3a4-2 | children < 5 years of age travelling internationally to areas where tuberculosis is prevalent.
BCG vaccination for individuals travelling to areas with a high incidence of disease is ideally administered 4-6 weeks prior to travel.
Tuberculin skin testing
Tuberculin skin testing (TST) or Mantoux testing prior to BCG vac... | mvec.mcri.edu.au/references/bcg-vaccine/index.html |
391a7ea2a3a4-3 | Side effects following vaccination
BCG, like all vaccines, has a list of common and expected side effects and a list of rare side effects that may occur in the weeks following vaccine administration.
Common and expected side effects can include:
a small red papule will appear at the injection site in the weeks followin... | mvec.mcri.edu.au/references/bcg-vaccine/index.html |
391a7ea2a3a4-4 | A/Prof Mike Starr
Craigieburn Specialist Consulting Suites
Medical One- QV
Kids Travel Doc
The Children’s Private Medical Group
Wyndham Private Medical Centre
Travel Clinics Australia- Caulfied
Travel Clinics Australia- Williams Landing
Other
MVEC: Intradermal vaccination
RCH Kids Health Information: Tuberculosis dise... | mvec.mcri.edu.au/references/bcg-vaccine/index.html |
489a2dc10416-0 | What is it?
Haemophilus influenzae is a type of bacteria that can live in a person’s nose and throat. It is considered part of the normal flora of the nasopharynx (upper respiratory tract) and generally does not cause symptoms of disease. However, when the bacteria invade other areas of the body, severe infections and ... | mvec.mcri.edu.au/references/haemophilus-influenzae-type-b-hib/index.html |
489a2dc10416-1 | Carriers may be symptomatic or asymptomatic. A person can transmit the bacteria for as long it is present in the nasopharynx.
Epidemiology
Before vaccination was included on the National Immunisation Program (NIP) in 1992, Hib was the biggest cause of invasive bacterial infection in children in Australia. Since then, ... | mvec.mcri.edu.au/references/haemophilus-influenzae-type-b-hib/index.html |
489a2dc10416-2 | Authors: Georgina Lewis (Clinical Manager SAEFVIC, Murdoch Children’s Research Institute) and Rachael McGuire (MVEC Education Nurse Coordinator)
Reviewed by: Rachael McGuire (MVEC Education Nurse Coordinator)
Date: July 4, 2023
Materials in this section are updated as new information and vaccines become available. The ... | mvec.mcri.edu.au/references/haemophilus-influenzae-type-b-hib/index.html |
bdc527b53ea7-0 | SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community) is the central reporting service in Victoria for any significant adverse event following immunisation (AEFI).
An AEFI is defined by the Australian Immunisation Handbook as “any untoward medical occurrence that follows immunisation. It does ... | mvec.mcri.edu.au/references/saefvic/index.html |
bdc527b53ea7-1 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/saefvic/index.html |
ed95f4d7bf27-0 | Background
Individuals undergoing cancer treatments (eg. chemotherapy, immunosuppressive therapies or haematopoietic stem cell transplants (HSCT)) are at a higher risk of contracting infectious diseases due to their malignancy, as well as the immune suppression caused by their treatment. Immune suppression can result i... | mvec.mcri.edu.au/references/cancer-immunisation-guideline-chemotherapy-and-post-haematopoietic-stem-cell-transplant_2/index.html |
ed95f4d7bf27-1 | MVEC: COVID-19 vaccination in children and adolescents
MVEC: Needle phobia
MVEC: Live-attenuated vaccines and immunoglobulins or blood products
Authors: Rachael McGuire (MVEC Education Nurse Coordinator) and Nigel Crawford (Director SAEFVIC, Murdoch Children’s Research Institute)
Reviewed by: Rachael McGuire (MVEC Educ... | mvec.mcri.edu.au/references/cancer-immunisation-guideline-chemotherapy-and-post-haematopoietic-stem-cell-transplant_2/index.html |
1b058519a069-0 | What is it?
Rotavirus gastroenteritis is caused by non-enveloped RNA viruses. It is a common cause of viral gastroenteritis in children. Globally, it is the most common cause of viral gastroenteritis related deaths in those less than 5 years of age.
What to look for
Rotavirus gastroenteritis classically occurs followin... | mvec.mcri.edu.au/references/rotavirus/index.html |
1b058519a069-1 | Vaccine
Dose
Route
Age range for 1st dose
Age range for 2nd dose
Age range for 3rd dose
Minimum interval between doses
Rotarix
2 doses (1.5ml/dose)
Oral*
6-14 weeks (not for administration once infant has turned 15 weeks of age)
10-24 weeks (not for administration once infant has turned 25 weeks of age)
NA
4 weeks
Rot... | mvec.mcri.edu.au/references/rotavirus/index.html |
1b058519a069-2 | Supportive therapies such as paracetamol and additional fluids (breastmilk/formula) can help manage symptoms. Good hand hygiene practices are particularly important when handling soiled nappies during this period to minimise the risk of transmission as the virus can shed in stools for 7-10 post immunisation.
Very rare ... | mvec.mcri.edu.au/references/rotavirus/index.html |
1b058519a069-3 | Contraindications
Rotavirus vaccine should not be given to any infant with a previous history of intussusception or a congenital bowel abnormality which pre-disposes them to intussusception.
Infants with severe combined immunodeficiency disorder (SCID) should not receive rotavirus vaccines due to the risks of vaccine-a... | mvec.mcri.edu.au/references/rotavirus/index.html |
4eefd45fcdbb-0 | English (Australia)
English (Australia)
हिन्दी
What is it?
Influenza viruses are single stranded RNA orthomyxoviruses which can cause acute viral infections of the respiratory tract. Infections are often classified according to the type of influenza virus responsible for the infection, typically A, B, or ... | mvec.mcri.edu.au/references/influenza-vaccine-recommendations/index.html |
4eefd45fcdbb-1 | Pregnant women, children < 5 years of age, those aged > 65 years, people with underlying medical conditions, and Aboriginal and Torres Strait Islander peoples carry the highest rates of morbidity and mortality within Australia.
Prevention
Influenza vaccination is available and recommended for anyone ≥ 6 months of age w... | mvec.mcri.edu.au/references/influenza-vaccine-recommendations/index.html |
4eefd45fcdbb-2 | In 2023 the influenza virus strains included in the seasonal influenza vaccines are the same for both cell-based and egg-based vaccines:
A/Sydney/5/2021 (H1N1) pdm09-like virus
A/Darwin/9/2021 (H3N2)-like virus
B/Austria/1359417/2019-like (B/Victoria lineage)-like virus
B/Phuket/3073/2013-like (B/Yamagata lineage)-like... | mvec.mcri.edu.au/references/influenza-vaccine-recommendations/index.html |
4eefd45fcdbb-3 | Table 1: The 2023 influenza vaccine brand recommendations according to age
Age Group Vaccine brand and dose Vaxigrip Tetra® (0.5 ml) Fluarix® Tetra (0.5 ml) Afluria® Quad (0.5 ml) FluQuadri® (0.5ml) Influvac® Tetra (0.5ml) Flucelvax® Quad (0.5ml) Fluad® Quad (0.5ml) Fluzone High-Dose Quad (0.7ml) < 6 months 6 months - ... | mvec.mcri.edu.au/references/influenza-vaccine-recommendations/index.html |
4eefd45fcdbb-4 | βFluarix-tetra®/FluQuadri®/Afluria Quad®/Vaxigrip tetra®/Influvac tetra®/ Flucelvax Quad® are registered for use in those aged ≥ 65 years however adjuvanted vaccines are the preferred vaccines for this age group.
^2 doses are recommended in the first year following SOT/HSCT regardless of history of influenza vaccinatio... | mvec.mcri.edu.au/references/influenza-vaccine-recommendations/index.html |
4eefd45fcdbb-5 | Do healthy people need to be immunised against influenza?Influenza can be a very serious disease resulting in hospitalisation and death. Even in cases where disease and its complications are not severe, it can cause a great inconvenience for the individual, including the cost of GP visits and medications, as well as ti... | mvec.mcri.edu.au/references/influenza-vaccine-recommendations/index.html |
4eefd45fcdbb-6 | In children < 9 years of age who received the influenza vaccine for the first time last year but only received 1 dose, how many doses are required this year?Only 1 dose is required in this instance. 2 doses of the influenza vaccine are recommended for children < 9 years of age in the first year of receiving the vaccine... | mvec.mcri.edu.au/references/influenza-vaccine-recommendations/index.html |
4eefd45fcdbb-7 | MVEC: Maternal vaccination during pregnancy
Authors: A/Prof Nigel Crawford (Director SAEFVIC, Murdoch Children’s Research Institute), Rachael McGuire (Research Nurse SAEFVIC, Murdoch Children’s Research Institute), Georgina Lewis (Clinical Manager SAEFVIC, Murdoch Children’s Research Institute) and Mel Addison (Researc... | mvec.mcri.edu.au/references/influenza-vaccine-recommendations/index.html |
d00fa60045f2-0 | The Paediatric Integrated Cancer Service (PICS) is a statewide initiative supported by Cancer Australia, with guidelines endorsed by the Australian and New Zealand Childrens Haemotology/Oncology Group (ANZHOG).
The PICS immunisation resources detail vaccines to consider during cancer therapy [e.g. influenza (flu)], as ... | mvec.mcri.edu.au/references/paediatric-integrated-cancer-service-pics-immunisation-resources/index.html |
8a810e9a8af1-0 | Immunisation assessment is an extremely important aspect of healthcare during pregnancy. When planning a pregnancy, talk to your health care provider about any vaccines you might need beforehand. Live-attenuated vaccines should be given at least a month before conception.
Recommended vaccines
Influenza, pertussis and C... | mvec.mcri.edu.au/references/pregnancy-and-vaccines/index.html |
8a810e9a8af1-1 | Maternal antibodies against pertussis provide protection for babies until they have at least received 2 doses of their own pertussis containing vaccine (given at 6-weeks and 4-months of age). Babies less than 6-months of age are at greatest risk of severe disease and death from pertussis.
COVID-19 vaccines
Due to an in... | mvec.mcri.edu.au/references/pregnancy-and-vaccines/index.html |
8a810e9a8af1-2 | Contraindicated vaccines
All live-attenuated vaccines are contraindicated during pregnancy due to the potential risk to the unborn baby [see Table 1 below]. In most circumstances the risk is hypothetical however, there is insufficient evidence to support vaccination in this patient group. The limited safety data from i... | mvec.mcri.edu.au/references/pregnancy-and-vaccines/index.html |
8a810e9a8af1-3 | Amirthalingam, G. et al Effectiveness of maternal pertussis vaccination in England: an observational study The Lancet October 2014 384(9953) 1521-1528
Steedman, M. et al Strategies to boost maternal immunization to achieve further gains in improved maternal and newborn health Health Affairs 2016 (35)309-316
Australian ... | mvec.mcri.edu.au/references/pregnancy-and-vaccines/index.html |
f127aa01e5f8-0 | Where a person’s immunisations are not up to date with the National Immunisation Program (NIP), it is important to arrange a catch up schedule for immunisations to be completed in the shortest and most effective time frame to ensure protection against vaccine preventable diseases.
Prior to commencing a catch up schedul... | mvec.mcri.edu.au/references/catch-up-immunisations/index.html |
f127aa01e5f8-1 | Date: January 31, 2022
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal ... | mvec.mcri.edu.au/references/catch-up-immunisations/index.html |
28dea811385f-0 | What is it?
Shoulder Injury Related to Vaccine Administration (SIRVA) is a rare but serious complication following suspected inadvertent administration of a vaccine too high in the deltoid or into the shoulder joint. This may cause a local inflammatory response and potential trauma to local structures within the should... | mvec.mcri.edu.au/references/shoulder-injury-related-to-vaccine-administration/index.html |
28dea811385f-1 | If radiological investigations such as ultrasound or MRI are undertaken to support or confirm a diagnosis, abnormalities including bursitis, adhesive capsulitis, impingement syndrome, synovitis or tendon tears may be identified.
Early diagnosis of SIRVA leads to timely treatment which is thought to lessen the duratio... | mvec.mcri.edu.au/references/shoulder-injury-related-to-vaccine-administration/index.html |
28dea811385f-2 | Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don’t aim too high: Avoiding shoulder injury related to vaccine administration. Aust Fam Physician 2016;45(5):303-306
Petrakis N, Addison M, Penak B, Schrader S, Mallard J, Clothier H. J , Buttery J. P, Crawford N. W & Cheng D. R (2023) Shoulder injury following CO... | mvec.mcri.edu.au/references/shoulder-injury-related-to-vaccine-administration/index.html |
c5457901b065-0 | A number of families and consumers and healthcare professionals have been asking MVEC staff about the MTHFR gene and possible adverse events following immunisation [AEFI]
MTHFR stands for methylenetetrahydrofolate reductase, which is the name of an enzyme involved in folate metabolism
MTHFR gene polymorphisms, or harml... | mvec.mcri.edu.au/references/mthfr-gene/index.html |
c5457901b065-1 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/mthfr-gene/index.html |
813b3e908e0d-0 | A hypotonic-hyporesponsive episode (HHE) is defined as the sudden onset of hypotonia (muscle limpness), reduced responsiveness or unresponsiveness and pallor or cyanosis occurring after vaccination in early childhood (< 2 years of age).
Most children are initially irritable and febrile prior to the event and respiratio... | mvec.mcri.edu.au/references/hypotonic-hyporesponsive-episode-hhe/index.html |
813b3e908e0d-1 | Treatment
These episodes self-resolve and often don’t need any treatment. However, the initial management should be for shock and include assessment of airway, breathing and circulation. Careful clinical observation and documentation of the event are vital for differential diagnosis. Urgent medical review is advised fo... | mvec.mcri.edu.au/references/hypotonic-hyporesponsive-episode-hhe/index.html |
813b3e908e0d-2 | Date: November 29, 2022
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal... | mvec.mcri.edu.au/references/hypotonic-hyporesponsive-episode-hhe/index.html |
5527f08b955c-0 | Background
Like any medication in development, vaccine candidates must undergo rigorous testing procedures and scientific evaluation to prove not only their effect on the targeted disease, but also to determine their safety, before being licensed and registered for use in vaccination programs. In Australia, the Therape... | mvec.mcri.edu.au/references/development-of-vaccines/index.html |
5527f08b955c-1 | A vaccine must pass all of these phases before it is registered for use by the TGA. Previously, approval of vaccines could take up to 10 years. However, the process has been streamlined throughout the COVID-19 pandemic and can now be completed in under 12 months, noting all of the appropriate clinical phase trials and ... | mvec.mcri.edu.au/references/development-of-vaccines/index.html |
5527f08b955c-2 | Provisional approval
Provisional approval has been the formal pathway used in Australia for speeding up access to COVID-19 vaccine candidates using preliminary clinical data. The provisional pathway allows for the temporary registration of promising medicines or vaccines based on early data, where the benefits of early... | mvec.mcri.edu.au/references/development-of-vaccines/index.html |
5527f08b955c-3 | Australian Academy of Science: How are vaccines shown to be safe?
The International Coalition of Medicines Regulatory Authorities: ICMRA statement about confidence in vaccine safety and effectiveness (for healthcare professionals)
The International Coalition of Medicines Regulatory Authorities: ICMRA statement about co... | mvec.mcri.edu.au/references/development-of-vaccines/index.html |
4095718a3c34-0 | What is it?
People with G6PD deficiency do not have enough of an enzyme (chemical) called glucose-6-phosphate dehydrogenase (G6PD). It is a genetic disorder which predominantly occurs in males.
Without G6PD, red blood cells are destroyed when exposed to certain foods, infections, medicines or chemicals. Red blood cells... | mvec.mcri.edu.au/references/g6pd-deficiency-and-vaccines/index.html |
4095718a3c34-1 | Date: November 30, 2022
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal... | mvec.mcri.edu.au/references/g6pd-deficiency-and-vaccines/index.html |
ea7402916395-0 | What is it?
Yellow fever is an acute viral haemorrhagic disease transmitted by infected mosquitos (arbovirus).
What to look for?
The incubation period of yellow fever is 3-6 days. The initial signs and symptoms are generally non-specific and include fever, chills, myalgia, fatigue and nausea or vomiting. Symptoms usual... | mvec.mcri.edu.au/references/yellow-fever/index.html |
ea7402916395-1 | Accredited yellow fever vaccination centres will provide vaccine recipients with an International Certificate of Vaccination or Prophylaxis as proof of vaccination. All travellers entering Australia who have been in a declared yellow fever infected country within 6 days of arrival to Australia must show proof of vaccin... | mvec.mcri.edu.au/references/yellow-fever/index.html |
ea7402916395-2 | Resources
DHHS: Yellow fever vaccination centres
Australian Immunisation Handbook: Yellow fever
Australian Government Department of Health: Yellow fever general fact sheet
World Health Organization: Yellow fever
Authors: Rachael McGuire (SAEFVIC Research Nurse, Murdoch Children’s Research Institute) and Daniela Say (MV... | mvec.mcri.edu.au/references/yellow-fever/index.html |
cabd36dc63d0-0 | What is it?
Q fever is caused by the bacteria Coxiella Burnetii.
What to look for
Infection is asymptomatic in at least half of cases. Those who experience symptoms may develop fever, chills, sweats, fatigue, severe headache, weakness, and muscle and joint pain. Complications can include hepatitis, pneumonia and endoca... | mvec.mcri.edu.au/references/q-fever/index.html |
cabd36dc63d0-1 | A B C D E F G H I J K L M N O P Q R S T U V W X Y Z | mvec.mcri.edu.au/references/q-fever/index.html |
fde6f891c4f7-0 | What are they?
Multi-dose vials contain more than one dose of a medicine/vaccine in a single vial. Whilst all vaccines on the National Immunisation Program are single-use preparations, BCG vaccines and COVID-19 vaccines are available in multi-dose vials in Australia. Multi-dose vials are more economical, take less time... | mvec.mcri.edu.au/references/multi-dose-vials/index.html |
fde6f891c4f7-1 | Multi-dose vials that require reconstitution
Only the recommended diluent should be used to reconstitute a multi-dose vial
Introduce the diluent down the side of the vial to avoid foaming or potentially denaturing the vaccine. Mix gently with a careful swirling motion. Do not shake
Give reconstituted vaccines as soon a... | mvec.mcri.edu.au/references/multi-dose-vials/index.html |
fde6f891c4f7-2 | ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination
ACIPC: Aseptic Technique Clinician Cheat Sheet
Canadian Immunization Guide: Vaccine administration practices
Center for Disease Control Injection Safety: Questions about multi-dose vials
Medical Journal of Australia: Vaccination, consent and multi-d... | mvec.mcri.edu.au/references/multi-dose-vials/index.html |
060cdb39cc48-0 | In 2016, the previously known Australian Childhood Immunisation Register (ACIR) expanded to an all of life register and became known as the Australian Immunisation Register (AIR). It is a national register recording the immunisations of all Australians of all ages.
Why should vaccines be recorded?
The AIR records any v... | mvec.mcri.edu.au/references/australian-immunisation-register/index.html |
060cdb39cc48-1 | Do patients need to be eligible for medicare in order to have an AIR record?
No. Everyone can have an AIR record. If a person does not have medicare, immunisations can still be recorded based on name, date of birth and address.
Immunisation history statements
An IHS can be used to keep track of vaccines that have been ... | mvec.mcri.edu.au/references/australian-immunisation-register/index.html |
185f6e9e0d35-0 | What is it?
Mpox is a viral zoonosis (an infection spread from animals to humans). It is caused by a virus that belongs to the Orthopoxvirus genus (which also causes the variola virus responsible for smallpox disease and the vaccinia virus, which is used in smallpox vaccines). Mpox was first discovered in 1958 and ther... | mvec.mcri.edu.au/references/monkeypox/index.html |
185f6e9e0d35-1 | The infection is usually self-limiting with symptoms lasting from 2-4 weeks. Complications can include secondary infection such as cellulitis, sepsis, infection of the cornea (which can be threaten vision), bronchopneumonia and encephalitis. The case fatality ratio is between 3-6%. More severe illness can occur in immu... | mvec.mcri.edu.au/references/monkeypox/index.html |
185f6e9e0d35-2 | ACAM2000™ – 2nd generation, live-attenuated vaccine
JYNNEOS® – 3rd generation, non-replicating vaccine
Recommendations
Either vaccine can be administered subcutaneously as either primary preventative vaccination (PPV) or post-exposure preventative vaccination (PEPV) based on an individual risk-benefit assessment. ATAGI... | mvec.mcri.edu.au/references/monkeypox/index.html |
185f6e9e0d35-3 | sex workers, particularly those with clients who belong to high-risk groups
anyone in the above categories planning to travel to a country experiencing a mpox outbreak (immunisation is recommended 4-6 weeks prior to travelling)
anyone at greater risk of poorer outcomes due to mpox infection, such as those with severe i... | mvec.mcri.edu.au/references/monkeypox/index.html |
185f6e9e0d35-4 | Vaccine Age Platform Route Volume Primary course Booster JYNNEOS® ≥ 18 years Non-replicating ankara vector Subcutaneous §0.5ml 2 doses, min. 28 days apart* If previous smallpox vaccine was received > 10 years ago Intradermal §€£0.1ml 2 doses, min. 28 days apart ACAM2000™ ¥≥ 18 years Live-attenuated Percutaneous ^#1 dro... | mvec.mcri.edu.au/references/monkeypox/index.html |
185f6e9e0d35-5 | # for full aftercare instructions, refer the product information
¥ ACAM2000 is a live-attenuated vaccine and therefore as outlined above, it’s use is contraindicated in some patient groups. For a full list of contraindications and precautions refer to the ATAGI clinical guidance on vaccination against Mpox.
Following v... | mvec.mcri.edu.au/references/monkeypox/index.html |
185f6e9e0d35-6 | Date: March 23, 2023
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal he... | mvec.mcri.edu.au/references/monkeypox/index.html |
f16bd1114cd2-0 | What is it?
The RCH Immunisation Service drop-in centre was established in March 2001.
The drop-in centre provides opportunistic vaccines for patients and parents at the hospital, and, where available, non-patients (appointments are required for catch-up immunisation plans). Led by a specialist nursing team (and run by... | mvec.mcri.edu.au/references/the-royal-childrens-hospital-immunisation-service-drop-in-centre/index.html |
f16bd1114cd2-1 | Contact
Telephone: Immunisation hotline 1300 882 924 (option 2) or direct (03) 9345 6599 / 9345 6399.
Pager: 4330 via hospital switchboard (03) 9345 5522.
Email: [email protected]
Facsimile: (03) 9345 4100.
Resources
The Royal Children’s Hospital, Immunisation Service Drop-in Centre
MVEC: BCG vaccine
MVEC: Influenza va... | mvec.mcri.edu.au/references/the-royal-childrens-hospital-immunisation-service-drop-in-centre/index.html |
474e9a4ced4e-0 | AusVaxSafety is an active national surveillance system of all vaccines on the National Immunisation Program (NIP), which monitors adverse events following immunisation (AEFI) to detect possible vaccine safety signals. With funding from the Australian Government Department of Health, it commenced in 2014 and is led by t... | mvec.mcri.edu.au/references/ausvaxsafety-vaccine-safety-surveillance-in-australia/index.html |
474e9a4ced4e-1 | A B C D E F G H I J K L M N O P Q R S T U V W X Y Z | mvec.mcri.edu.au/references/ausvaxsafety-vaccine-safety-surveillance-in-australia/index.html |
0200ed2b4407-0 | A number of families and health care providers may wonder if immunisations are permitted based on religious beliefs, given the presence of gelatin derived from pork in some vaccines.
Leaders of the Jewish faith have declared that pork derived additives in medicines are permitted for those observant of the Jewish faith.... | mvec.mcri.edu.au/references/porcine-gelatin-and-vaccines/index.html |
0200ed2b4407-1 | Date: February 2019
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal hea... | mvec.mcri.edu.au/references/porcine-gelatin-and-vaccines/index.html |
17c1a3420144-0 | Thrombosis with thrombocytopenia syndrome (TTS), also known as Vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or vaccine-induced immune thrombotic thrombocytopenia (VITT), was a rare syndrome reported in people who received adenoviral vector COVID-19 vaccines such as Vaxzevria (AstraZeneca) and the Johns... | mvec.mcri.edu.au/references/thrombosis-with-thrombocytopenia-syndrome/index.html |
17c1a3420144-1 | platelet count < 150,000 per microliter
positive anti-PF4 ELISA result is required.
Tier 1 tends to be associated with more severe presentations and carries a higher risk of morbidity and mortality than Tier 2. Evidence suggests that Tier 1 is more common in younger age groups.
How did adenoviral vector vaccines tri... | mvec.mcri.edu.au/references/thrombosis-with-thrombocytopenia-syndrome/index.html |
17c1a3420144-2 | Resources
MJA: Australian and New Zealand approach to diagnosis and management of vaccine‐induced immune thrombosis and thrombocytopenia
Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) Multidisciplinary VITT Guideline for Doctors
HealthPathways Thrombosis with Thrombocytopenia Syndrome (TTS) pat... | mvec.mcri.edu.au/references/thrombosis-with-thrombocytopenia-syndrome/index.html |
17c1a3420144-3 | Date: May 2, 2023
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal healt... | mvec.mcri.edu.au/references/thrombosis-with-thrombocytopenia-syndrome/index.html |
157fa17dce6e-0 | What is gelatin
Gelatin is a protein product derived from collagen. It is added to some vaccines to act as a stabiliser to ensure they remain effective after manufacture. The type of gelatin used in vaccines (usually porcine in origin) is different from the gelatin used in foods (usually bovine in origin) and is highly... | mvec.mcri.edu.au/references/gelatin-allergy-and-vaccines/index.html |
157fa17dce6e-1 | Australian Immunisation Handbook: Components of vaccines used in Australia
Authors: Adele Harris (SAEFVIC Research Nurse, Murdoch Children’s Research Institute), Nigel Crawford (Director, SAEFVIC, Murdoch Children’s Research Institute), Kirsten Perrett (Clinician Scientist Fellow, Murdoch Children’s Research Institute)... | mvec.mcri.edu.au/references/gelatin-allergy-and-vaccines/index.html |
5d6310fcc6cf-0 | Background
Immune thrombocytopenia, also previously known as idiopathic thrombocytopenia purpura (ITP), is an uncommon autoimmune condition in which the body’s own immune system attacks platelets (the cells found in the blood which normally help the blood to clot). In ITP, the body produces antibodies which attack and ... | mvec.mcri.edu.au/references/immune-thrombocytopenia-itp/index.html |
5d6310fcc6cf-1 | ITP and measles, mumps and rubella vaccines (MMR)
MMR vaccines have been associated with ITP, with the risk estimated at approximately 1 in 25,000 vaccinations. However, the risk of ITP following MMR vaccine is much lower than the risk seen with natural measles or rubella infections. Patients with a history of ITP are... | mvec.mcri.edu.au/references/immune-thrombocytopenia-itp/index.html |
5d6310fcc6cf-2 | Should patients with a history of ITP receive COVID-19 vaccines?
Yes. The effect of COVID-19 vaccination on pre-existing ITP (acute and chronic) has not been well characterised. Limited and early data indicates that vaccination may worsen thrombocytopenia in approximately 10% of patients with chronic ITP post vaccinati... | mvec.mcri.edu.au/references/immune-thrombocytopenia-itp/index.html |
5d6310fcc6cf-3 | If a patient (> 18 years) has ITP following a dose of Vaxzevria (AstraZeneca), they should receive an mRNA vaccine (eg. Comirnaty or Spikevax) or Nuvaxovid (Novavax) for their subsequent doses. If a patient has ITP following the first dose of an mRNA vaccine or Nuvaxovid they should proceed with the second dose of the ... | mvec.mcri.edu.au/references/immune-thrombocytopenia-itp/index.html |
5d6310fcc6cf-4 | Bhattacharjee S, Banerjee M. Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review. SN Compr Clin Med. 2020:1-11
Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.... | mvec.mcri.edu.au/references/immune-thrombocytopenia-itp/index.html |
5d6310fcc6cf-5 | Date: July 21, 2022
Materials in this section are updated as new information and vaccines become available. The Melbourne Vaccine Education Centre (MVEC) staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal hea... | mvec.mcri.edu.au/references/immune-thrombocytopenia-itp/index.html |
aba540f7ad7e-0 | Background
Eczema, or atopic dermatitis, is a skin condition affecting many people of all ages but is most common in infants and young children. It affects approximately 40% of babies and children worldwide and often appears in the first year of life. Many children grow out of eczema around the age of 5 years however, ... | mvec.mcri.edu.au/references/eczema-and-immunisations/index.html |
aba540f7ad7e-1 | Precautions
If there is active eczema at the intended site of injection, an alternate site could be considered to reduce the risk of infection (or abscess). If no other site is deemed suitable, cleaning the site with an alcohol-based wash/single use alcohol swab and allowing the site to dry completely before injecting ... | mvec.mcri.edu.au/references/eczema-and-immunisations/index.html |
aba540f7ad7e-2 | You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family’s personal health. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult a healthcare professional.
A B C D E F... | mvec.mcri.edu.au/references/eczema-and-immunisations/index.html |
16baf513b07c-0 | What is it?
The Monash Health Immunisation Service was established in 2012.
It is a nurse-led, all-age immunisation drop-in service, with adult and paediatric immunisation physician support and clinics. The service provides immunisation education and management for high risk groups including oncology, renal, diabetic, ... | mvec.mcri.edu.au/references/monash-health-immunisation-service/index.html |
16baf513b07c-1 | MVEC: Influenza vaccine recommendations
MVEC: The VicSIS Network
Authors: Joanne Hickman (NUM Monash Immunisation, Monash Health), Jim Buttery (Paediatrician/ ID physician, Monash Health) and Rachael McGuire (SAEFVIC Research Nurse, Murdoch Children’s Research Institute)
Reviewed by: Francesca Machingaifa (MVEC Educati... | mvec.mcri.edu.au/references/monash-health-immunisation-service/index.html |
f1aa3844ae43-0 | Background
Postural tachycardia syndrome (POTS) is a syndrome where individuals experience a cluster of symptoms including an inappropriate level of tachycardia (rapid heartbeat) upon standing. The condition is more common in females, especially adolescents and young adults. There can be a number of associated symptom... | mvec.mcri.edu.au/references/pots-postural-tachycardia-syndrome-and-immunisation/index.html |
f1aa3844ae43-1 | Human papillomavirus (HPV)
There have been concerns previously after a small number of case reports described POTS being diagnosed following human papillomavirus (HPV) vaccination. However, this has been thoroughly assessed by the Centers for Disease Control and Prevention (CDC) and after examining the data from more t... | mvec.mcri.edu.au/references/pots-postural-tachycardia-syndrome-and-immunisation/index.html |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.